By Gary Hu
Volume 10, Issue 2 (Winter 2011/2012)
More and more companies are encountering added pressures to reduce costs, risks, and time-to-market while maximizing efficiencies. They have converged on a common strategy of outsourcing non-core functions. A trend is developing where companies as small as start-up biotechs to the major pharmaceutical and biopharmaceutical producers are outsourcing their peptide production needs. Whether a company needs research or GMP-grade materials, they are realizing enhanced cost-effectiveness and efficiency by doing so…
Citation: Hu G. Strategies for Outsourcing Peptide Contract Manufacturing. BioProcess J, 2011; 10(2): 14-16. https://dx.doi.org/10.12665/J102.Hu
Posted online December 22, 2011